Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FPPRGD2 PET imaging in cancer
NCT01806675Phase 2Completed
- Start
- Mar 2013
- Primary completion
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 18F-FPPRGD2 in glioblastoma multiforme (GBM), gynecological cancer, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), breast cancer. Started Mar 2013; status: completed.
02
Drugs
18F-FPPRGD2
03
Conditions
glioblastoma multiforme (GBM)gynecological cancerrenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT01806675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806675.